Cell Therapeutics has announced that its drug Zevalin improved the median progression-free survival period among patients with CD-2-positive follicular non-Hodgkin's lymphoma when used as first-line consolidation treatment. The Phase III First Line Indolent Trial also showed that the use of the drug as first-line consolidation converted 77% of patients from partial remission after induction therapy to either complete remission or unconfirmed complete remission.

Full Story:
RTT News

Related Summaries